Mr. Raj Kannan serves as Chief Executive Officer and Director at I-Mab since June 22, 2023. He served as Chief Executive Officer and Director at Aerie Pharmaceuticals, Inc since December 20, 2021 until Nov...

리더십 팀

이름	위치	테뉴어	보상	소유권
Raj Kannan	CEO & Director	1.1yrs	데이터 없음	데이터 없음
Skelton Joseph	Chief Financial Officer	less than a year	데이터 없음	데이터 없음
Tianyi Zhang	Vice President of Investor Relations	no data	데이터 없음	데이터 없음
Fernando J. Salle´s	Senior VP and Head of U.S. & EU Business Development	4.3yrs	데이터 없음	데이터 없음
Louie Naumovski	Interim Chief Medical Officer	less than a year	데이터 없음	데이터 없음
Phillip Dennis	Chief Medical Officer	less than a year	데이터 없음	데이터 없음
Tyler Ehler	Senior Director of Investor Relations	no data	데이터 없음	데이터 없음

0.4yrs

평균 재임 기간

경험이 풍부한 관리: IMAB 의 관리팀은 경험 (평균 재직 기간 0.7 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Raj Kannan	CEO & Director	1.1yrs	데이터 없음	데이터 없음
Eric Rowinsky	Member of Scientific Advisory Board	5.1yrs	데이터 없음	데이터 없음
Roy Steven Herbst	Member of Scientific Advisory Board	5yrs	데이터 없음	데이터 없음
Howard L. Weiner	Member of Scientific Advisory Board	5yrs	데이터 없음	데이터 없음
Pamela M. Klein	Interim Chairperson	4.5yrs	데이터 없음	데이터 없음
Chia-Hung Yang	Independent Director	4.5yrs	데이터 없음	데이터 없음
Chun Kwok Au	Independent Director	4.5yrs	데이터 없음	데이터 없음
Wei Fu	Director	6.1yrs	데이터 없음	데이터 없음
Timothy A. Yap	Member of Scientific Advisory Board	4.9yrs	데이터 없음	데이터 없음
Ruyi He	Independent Director	3.1yrs	데이터 없음	데이터 없음
Patricia LoRusso	Member of Scientific Advisory Board	5yrs	데이터 없음	데이터 없음
Jun Ma	Member of Scientific Advisory Board	3.6yrs	데이터 없음	데이터 없음

4.7yrs

평균 재임 기간

61yo

평균 연령

경험이 풍부한 이사회: IMAB 의 이사회는 경험(평균 재직 기간 4.6 년)으로 간주됩니다.

I-Mab 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

I-Mab Appoints Phillip Dennis as Chief Medical Officer

I-Mab Announces Board Changes , Effective February 10, 2024

Member of Scientific Advisory Board notifies of intention to sell stock

Chief Legal Officer notifies of intention to sell stock

Chief Legal Officer notifies of intention to sell stock

Member of Scientific Advisory Board notifies of intention to sell stock

Recent updates

I-Mab Appoints Phillip Dennis as Chief Medical Officer

I-mab Biopharma (Hangzhou) Co., Ltd. completed the acquisition of I-Mab Biopharma (Shanghai) Co., Ltd. from I-Mab (NasdaqGM:IMAB).

I-mab Biopharma (Hangzhou) Co., Ltd. completed the acquisition of I-Mab Biopharma (Shanghai) Co., Ltd. from I-Mab (NasdaqGM:IMAB).

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates upgraded to CN¥12.72 loss

I-Mab: Trading Below Net Cash With Multiple Upside Options

I-mab Biopharma (Hangzhou) Co., Ltd. agreed to acquire I-Mab Biopharma (Shanghai) Co., Ltd. from I-Mab (NasdaqGM:IMAB) for $80 million.

I-mab Biopharma (Hangzhou) Co., Ltd. agreed to acquire I-Mab Biopharma (Shanghai) Co., Ltd. from I-Mab (NasdaqGM:IMAB) for $80 million.

I-Mab Announces Board Changes , Effective February 10, 2024

Member of Scientific Advisory Board notifies of intention to sell stock

Chief Legal Officer notifies of intention to sell stock

Price target decreased by 17% to US$21.56

Chief Legal Officer notifies of intention to sell stock

I-Mab and Hi-Bio Announces That the U.S. Food and Drug Administration Has Granted Breakthrough Therapy Designation for Felzartamab, an Investigational Cd38 Antibody, for the Treatment of Primary Memorbranous Nephropathy (PMN)

I-Mab Announces Phase 1 Data of Givastomig at Esmo 2023

I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1Bb Bispecific Antibody Tj-L14b Abl503

New minor risk - Share price stability

Consensus revenue estimates fall by 15%

Consensus revenue estimates fall by 78%

Price target decreased by 19% to US$24.47

I-Mab (NasdaqGM:IMAB) announces an Equity Buyback for $40 million worth of its shares.

I-Mab to Report First Half, 2023 Results on Aug 17, 2023

Member of Scientific Advisory Board notifies of intention to sell stock

I-Mab Announces the Appointment of Raj Kannan as Member of the Board of Directors

TRACON Pharmaceuticals, Inc. Announces Enforcement Action to Collect Binding Arbitration Award from I-Mab Biopharma

Price target increased by 8.5% to US$27.65

Interim CFO notifies of intention to sell stock

Price target increased by 7.2% to US$27.30

Price target decreased by 11% to US$29.81

Price target decreased by 7.7% to US$33.57

We're Keeping An Eye On I-Mab's (NASDAQ:IMAB) Cash Burn Rate

Member of Scientific Advisory Board notifies of intention to sell stock

Price target decreased to US$36.38

Less than half of directors are independent

First half 2022 earnings: EPS and revenues miss analyst expectations

I-Mab Announces Management Changes

I-Mab Announces Executive Changes

I-Mab: Another CD47 Inhibitor Biotech With Great Potential

I-Mab(NasdaqGM:IMAB) dropped from FTSE All-World Index (USD)

I-Mab Announces Approval from China CDE to Initiate Phase 3 Registrational Study of Lemzoparlimab in Combination with Azacitidine in Higher-Risk Myelodysplastic Syndrome

I-Mab gets Chinese nod to start phase 3 combo treatment trial for myelodysplastic syndrome

I-Mab Announces Positive Phase 2 Data of Lemzoparlimab in Combination with Azacitidine (AZA) in Patients with Higher Risk Myelodysplastic Syndrome at ESMO 2022

Consensus revenue estimates fall by 63%

I-Mab (NasdaqGM:IMAB) announces an Equity Buyback for $40 million worth of its shares.

I-Mab Biopharma Non-GAAP EPADS of -$1.54, revenue of $7.74M

I-Mab and senior executives may buy $40M worth of shares; stock up 10%

Newsflash: I-Mab (NASDAQ:IMAB) Analysts Have Been Trimming Their Revenue Forecasts

I-Mab to Report First Half, 2022 Results on Aug 30, 2022

Consensus revenue estimates fall by 13%

Price target decreased to US$58.94

I-Mab Announces First Patient Dosed in Phase 1 Clinical Trial of Claudin 18.2 and 4-1Bb Bispecific Antibody TJ-CD4B in Solid Tumors in China

I-Mab doses first patient in phase 1 trial of TJ-CD4B in solid tumors in China

I-Mab Valuation Offers A Biotech Investment Opportunity

Genexine Announces Completion of Enrollment in Phase 3 Clinical Trial with Its Proprietary Long-acting Growth Hormone, GX-H9/TJ101 (Eftansomatropin alfa)

I-Mab Announces Completion of Patient Enrollment in Phase III Clinical Trial of Eftansomatropin Alfa for Treatment of Pediatric Growth Hormone Deficiency

Price target decreased to US$74.89

I-Mab Reports Latest Phase 2 Clinical Data of its Differentiated CD73 Antibody Uliledlimab

Companies Like I-Mab (NASDAQ:IMAB) Are In A Position To Invest In Growth

I-Mab to Hold Investor Call to Report Latest Phase 2 Clinical Data of its Differentiated CD73 Antibody Uliledlimab

I-Mab Shaken By Management Moves, Merger Talk And Delisting Threat

I-Mab Reportedly Exploring Possible Sale Amid Takeover Interest

Consensus revenue estimates fall by 32%

Price target decreased to US$87.94

Bearish: Analysts Just Cut Their I-Mab (NASDAQ:IMAB) Revenue and EPS estimates

Founder notifies of intention to sell stock

I-Mab Announces First Patient Dosed in China Phase 2 Combination Trial of Lemzoparlimab with Toripalimab in Patients with Advanced Solid Tumors

I-Mab Announces First Patient Dosed in China Phase 2 Clinical Trial of Efineptakin Alfa in Combination with Pembrolizumab in Advanced Solid Tumors

Chief Commercial Officer notifies of intention to sell stock

Director notifies of intention to sell stock